Meeting
2016 Genitourinary Cancers Symposium
An open-label, single-group, phase 2 study of brentuximab vedotin as salvage therapy for males with relapsed germ-cell tumors (GCT): Results at the end of first stage (FM12GCT01).
Authors
Andrea Necchi
Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
Andrea Necchi , Domenico Magazzu , Andrea Anichini , Daniele Raggi , Patrizia Giannatempo , Nicola Nicolai , Maurizio Colecchia , Biagio Paolini , Elisa Coradeschi , Elena Tassi , Giulia Grazia , Roberta Mortarini , Giuseppina Calareso , Elena Togliardi , Flavio Crippa , Roberto Salvioni , Alessandro M. Gianni , Pinuccia Valagussa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Penile, Urethral, and Testicular Cancers
Clinical Trial Registration Number
NCT01851200
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 480)
DOI
10.1200/jco.2016.34.2_suppl.480
Abstract #
480
Poster Bd #
L5
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Activity of pazopanib in chemo-resistant patients with germ cell tumors (GCT): First results of the open-label, single-group, phase II PAZOTEST-01 trial.
First Author: Patrizia Giannatempo
Poster
2020 ASCO Virtual Scientific Program
Olaparib as salvage treatment for advanced germ cell tumors after chemotherapy failure: Results of the open-label, single-arm, IGG-02 phase II trial.
First Author: Ugo De Giorgi
Poster
2020 ASCO Virtual Scientific Program
A phase II open-label multicenter study to assess the efficacy and safety of AFM13 in patients with relapsed or refractory CD30‑positive peripheral T-cell lymphoma or transformed mycosis fungoides: The REDIRECT study design and rationale.
First Author: Cassandra Choe-Juliak
Poster
2017 Genitourinary Cancers Symposium
Pazopanib (PZP) in germ cell tumors (GCT) after chemotherapy (CT) failure: Final results of the open label, single-group, phase II Pazotest trial.
First Author: Andrea Necchi